Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart study tests tailored drugs for mysterious chest pain

NCT ID NCT07498231

Knowledge-focused Sponsor: Medical University of Bialystok Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at people who have chest pain but no major blockages in their heart arteries. Researchers will test if giving medication based on the specific type of tiny blood vessel problem (endotype) works better than standard care. About 180 participants will be followed for 6 months to see if their quality of life and symptoms improve.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: a. Chronic coronary syndrome c. Anginal symptoms \> CCS class I or angina equivalent d. Myocardial ischemia confirmed by non-invasive testing e. Provision of informed consent to participate in the study Exclusion Criteria: 1. Angiographically significant coronary artery stenosis or FFR \< 0.8 2. Renal insufficiency with eGFR \< 30 ml/min/1.73 m² 3. Left ventricular ejection fraction \< 40% 4. Hypertrophic cardiomyopathy 5. Acute coronary syndrome within \< 90 days 6. Percutaneous coronary intervention (PCI) within \< 90 days 7. Previous coronary artery bypass grafting (CABG) 8. Anemia \< 10 g/dL or thrombocytopenia \< 100,000/µL 9. Intraventricular conduction disturbances preventing ST-T segment assessment 10. Severe concomitant valvular heart disease 11. Active malignancy 12. Type 1 diabetes mellitus 13. Coronary artery anatomical abnormalities precluding assessment using PressureWire X (myocardial bridge causing \> 50% luminal narrowing of the investigated vessel, severe coronary tortuosity, inability to properly cannulate coronary ostia) 14. Pregnancy 15. Heart failure ≥ NYHA class III 16. Asthma or COPD with severe irreversible airflow obstruction 17. Atrial fibrillation 18. Second- or third-degree atrioventricular block without pacemaker implantation (IPG) 19. Manifest pre-excitation on ECG or history of AVRT episodes without prior ablation of the accessory pathway

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder myocardial ischemia nonobstructive coronary artery disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease Doppler echocardiography Echocardiography Microcirculation resistance Microcirculation; biomarkers; myocardial ischemia Microcirculatory dysfunction Microcirculatory status

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Clinical Hospital, Department of Invasive Cardiology, Internal Medicine with CICU and Catheterization Laboratory-Uniwersytecki Szpital Kliniczny w Białymstoku, Klinika Kardiologii Inwazyjnej, Chorób Wewnętrznych z OIOK i Pracownią Hemodynamiki

    RECRUITING

    Bialystok, 15-276, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.